Snap-8 (Acetyl Octapeptide-3)

Snap-8 is the trade name for acetyl octapeptide-3 (INCI), the N-acetylated, C-amidated octapeptide Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. It is an elongation of acetyl hexapeptide-3/-8, better known as argireline (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2), with Ala-Asp appended at the C-terminus. Both sequences are patterned on the N-terminal region of SNAP-25, one of the three proteins that assemble into the SNARE complex driving calcium-dependent vesicle fusion at the neuromuscular junction. The peptides were designed at Lipotec as topical cosmetic ingredients intended to mimic, weakly and reversibly, the endpoint of botulinum toxin (reduced acetylcholine release at expression lines) without any of its toxicity [1]. Snap-8 is a small synthetic peptide; it is not a botulinum toxin, does not cleave SNAP-25, and is regulated as a cosmetic ingredient, not a drug.

Mechanism as reported

Blanes-Mira et al. (2002) described the rational-design programme that produced argireline. In vitro, the hexapeptide interfered with the formation and/or stability of the SNARE complex and inhibited neurotransmitter release from a cellular model with a potency described as similar to botulinum toxin A but, as expected for a competitive peptide rather than a protease, far lower efficacy. In healthy women volunteers, an oil-in-water emulsion containing 10% of the hexapeptide reduced wrinkle depth by up to 30% after 30 days by skin-topography analysis, with no oral toxicity or primary irritation at high doses [1]. The proposed mechanism is competition: the peptide resembles the SNAP-25 N-terminus and destabilises assembly of the ternary SNAP-25/syntaxin/VAMP complex, damping exocytosis. Snap-8 extends the same sequence by two residues; the manufacturer's rationale is higher affinity for the complex, and reviews of cosmeceutical peptides place it in the same “neurotransmitter-inhibiting” class as argireline [3][4].

What has been tested

Independent clinical data exist for argireline rather than Snap-8. Wang et al. (2013) ran a randomised, placebo-controlled study in 60 Chinese subjects who applied 10% argireline or placebo to periorbital wrinkles twice daily for four weeks. The subjective overall anti-wrinkle response was 48.9% in the argireline group versus 0% with placebo, and silicone-replica roughness parameters fell significantly only in the treated group [2]. For Snap-8 itself, the indexed evidence is a 12-week monocentric clinical study of hyaluronic-acid dissolving microneedle patches whose formulation combined acetyl octapeptide-3 with arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts; fine lines decreased by 25.8%, hydration improved by 15.4% and dermal density and thickness rose by 14.2% and 12.9%, with no skin reactions reported [5]. Because the formulation contained several actives and a microneedle delivery system, no effect can be attributed to Snap-8 alone. Broader reviews of topical peptides catalogue Snap-8 among signal, carrier and neurotransmitter-inhibitor peptides and emphasise that most cosmetic evidence in the class is manufacturer-generated [3][4][6].

Skin penetration and formulation

A recurrent theme in the reviews is delivery. Peptides of 800–1100 Da with multiple charged residues (Snap-8 carries two glutamates, two arginines and an aspartate) penetrate intact stratum corneum poorly, which is why formulation studies use penetration enhancers, microneedles or lipid carriers [4][5][6]. In-vitro assays of SNARE-complex interference are performed on cell lysates or permeabilised cells and do not address whether topically applied peptide reaches the neuromuscular junction at all. The acetyl cap and C-terminal amide are there to slow exopeptidase degradation and neutralise terminal charges.

What the research does not establish

No peer-reviewed study isolates the effect of acetyl octapeptide-3 alone in humans; the argireline trial [2] concerns the shorter parent peptide, and the microneedle study [5] combined it with other actives. The claim that the octapeptide has higher SNARE affinity than the hexapeptide comes from manufacturer data rather than independent publications. No study shows that topically applied Snap-8 reaches motor nerve terminals, and the 30% and 48.9% figures are topographic and subjective wrinkle measures over four to twelve weeks, not muscle-activity measurements. Nothing establishes systemic effects of any kind, and comparisons with botulinum toxin describe a design intent, not demonstrated equivalence. This material is supplied strictly for in-vitro laboratory research.

Format. Lyophilized powder in a sealed glass vial. Stated mass refers to the peptide (acetate salt).

Reconstitution. Reconstitute with sterile or bacteriostatic water, directing the stream against the glass wall and swirling gently until dissolved. The peptide is water-soluble; for formulation work it is typically dissolved first and then incorporated into the aqueous phase. Our reconstitution calculator converts vial mass and diluent volume into concentration.

Storage. Lyophilized vials are typically stored at −20 °C and protected from light. Reconstituted solutions are generally refrigerated at 2–8 °C. The methionine at position 3 is oxidation-prone, so avoid peroxide-containing or heavily aerated formulations and aliquot before freezing to limit freeze-thaw cycles.

Handling. Standard laboratory practice applies: appropriate PPE, aseptic technique when reconstituting, and disposal in line with your institution's procedures. For in-vitro laboratory research only — not for human or veterinary use.